Taiwan FDA Drops Antibody Type Over Risks Of Severe Side Effects
This article was originally published in PharmAsia News
Executive Summary
Taiwan's FDA said it would withdraw certificates for the antibiotic oral chloramphenicol after recent research linked the drug to bone-marrow suppression, aplastic anemia and other severe side effects.